Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib
Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib
Studying samples of blood in the laboratory from patients receiving erlotinib may help
 doctors learn more about the effects of erlotinib on hormone levels.

 This clinical trial is looking at hormone changes in women with stage IIIB or stage IV
 non-small cell lung cancer receiving erlotinib.
Patients undergo a dermatology evaluation and complete the Polycystic Ovarian Syndrome (PCOS)
 research study questionnaire once. Blood samples are collected after an overnight fast.
 Samples are analyzed for circulating levels of total and bioavailable testosterone,
 dehydroepiandrosterone sulfate, and sex hormone binding globulin. Serum luteinizing hormone,
 follicle stimulating hormone, fasting glucose, and insulin levels are also assessed.
-  Histologically confirmed non-small cell lung cancer

 -  Stage IIIB (effusion) or stage IV disease

 -  Must be receiving daily erlotinib hydrochloride for more than 3 months

 -  Must have hirsutism, acne, androgenic alopecia, amenorrhea, truncal weight gain, or
 other clinical phenotype associated with syndrome of androgen excess